A novel thienopyrimidine analog, tph104, mediates immunogenic cell death in triple-negative breast cancer cells

Keyphrases

• Triple-negative Breast Cancer Cells 100%
• Immunogenic Cell Death 100%
• Supernatant 66%
• MDA-MB-231 Cells 66%
• Dendritic Cells 66%
• Tumor 33%
• Microenvironment 33%
• MRNA Level 33%
• MDA-MB-231 Cancer Cells 33%
• Plasma Membrane 33%
• Interleukin-12 (IL-12) 33%
• Cell Death 33%
• MRNA Expression 33%
• IC50 Value 33%
• ATP Level 33%
• Mouse Bone Marrow 33%
• MHC Class II 33%
• MDA-MB-231 33%
• Triple-negative Breast Cancer 33%
• Immuno 33%
• Conventional Chemotherapy 33%
• Genic 33%
• Immunogenic 33%
• Dendritic Cell Maturation 33%
• CD86 33%
• Bone Marrow-derived Dendritic Cells 33%
• Breast Cancer Susceptibility 33%
• Calreticulin 33%

Biochemistry, Genetics and Molecular Biology

• Cancer Cell 100%
• Cell Death 100%
• Dendritic Cell 100%
• Tumor Necrosis Factor 66%
• Messenger RNA 66%
• Adenosine Triphosphate 33%
• Cell Membrane 33%
• IC50 33%
• Supernatant 33%
• Intravenous Immunoglobulin 33%
• Cell Maturation 33%
• Calreticulin 33%

Immunology and Microbiology

• Cell Death 100%
• Cancer Cell 100%
• Tumor Necrosis Factor 66%
• Dendritic Cell 66%
• Supernatant 33%
• IC50 33%
• Cell Membrane 33%
• Intravenous Immunoglobulin 33%
• Breast Cancer Cell Line 33%
• Cell Maturation 33%
• CD86 33%
• Bone Marrow Derived Dendritic Cell 33%
• Calreticulin 33%